These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

715 related items for PubMed ID: 16678644

  • 1. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM.
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [Abstract] [Full Text] [Related]

  • 2. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA, Amonkar MM, Hebborn A, Altman R.
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [Abstract] [Full Text] [Related]

  • 3. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study.
    van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, Goettsch WG, Herings RM.
    Curr Med Res Opin; 2006 Sep; 22(9):1757-64. PubMed ID: 16968579
    [Abstract] [Full Text] [Related]

  • 4. Determinants of persistence with weekly bisphosphonates in patients with osteoporosis.
    Jones TJ, Petrella RJ, Crilly R.
    J Rheumatol; 2008 Sep; 35(9):1865-73. PubMed ID: 18709688
    [Abstract] [Full Text] [Related]

  • 5. Factors contributing to compliance with osteoporosis medication.
    Kertes J, Dushenat M, Vesterman JL, Lemberger J, Bregman J, Friedman N.
    Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J, Takeda T, Sato Y.
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [Abstract] [Full Text] [Related]

  • 7. Prescriptions for vitamin D among patients taking antiresorptive agents in Canada.
    Hanley DA, Zhang Q, Meilleur MC, Mavros P, Sen SS.
    Curr Med Res Opin; 2007 Jun; 23(6):1473-80. PubMed ID: 17559742
    [Abstract] [Full Text] [Related]

  • 8. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.
    Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F.
    Curr Med Res Opin; 2007 Mar; 23(3):585-94. PubMed ID: 17355739
    [Abstract] [Full Text] [Related]

  • 9. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F, Borges JL, Curiel MD.
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [Abstract] [Full Text] [Related]

  • 10. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
    Rietbrock S, Olson M, van Staa TP.
    QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
    [Abstract] [Full Text] [Related]

  • 11. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
    Thomson AB, Marshall JK, Hunt RH, Provenza JM, Lanza FL, Royer MG, Li Z, Blank MA, Risedronate Endoscopy Study Group.
    J Rheumatol; 2002 Sep; 29(9):1965-74. PubMed ID: 12233894
    [Abstract] [Full Text] [Related]

  • 12. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD, Faraawi RY, O'Mahony MF, Nayar A, Massaad R, Evans JK, Yacik C.
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
    Goeree R, Blackhouse G, Adachi J.
    Curr Med Res Opin; 2006 Jul; 22(7):1425-36. PubMed ID: 16834841
    [Abstract] [Full Text] [Related]

  • 15. Loss of treatment benefit due to low compliance with bisphosphonate therapy.
    Penning-van Beest FJ, Erkens JA, Olson M, Herings RM.
    Osteoporos Int; 2008 Apr; 19(4):511-7. PubMed ID: 17874028
    [Abstract] [Full Text] [Related]

  • 16. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD.
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [Abstract] [Full Text] [Related]

  • 17. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.
    Penning-van Beest FJ, Erkens JA, Olson M, Herings RM.
    Curr Med Res Opin; 2008 May; 24(5):1337-44. PubMed ID: 18380910
    [Abstract] [Full Text] [Related]

  • 18. Compliance of osteoporotic patients with different treatment regimens.
    Segal E, Tamir A, Ish-Shalom S.
    Isr Med Assoc J; 2003 Dec; 5(12):859-62. PubMed ID: 14689753
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H.
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.